U.S. markets closed

GB Sciences, Inc. (GBLX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0451-0.0014 (-2.96%)
At close: 2:45PM EDT
Sign in to post a message.
  • w
    willy
    OK, my dd shows me there is no money here. gblx working on an important delivery platform could very well show positive results. no money? Earnings expected Aug 28th. Now I understand why the SP is sinking and will most probably continue down to .02-.03 before Aug 28. I believe if there will be no major breakthrough, your SP will be going to 0 and goodbye. cheers & beers to all
  • L
    LAZYDAD
    Excellent direction for Dr. Andrea Small-Howard (too long time coming) Hope you become the person that GBLX needs to put things in the right direction Your forte is science But throw that experience in the executive field by the reigns Bring it on !!
  • W
    What'sup
    it will start making money when the sell the use of rights to other companies... $$$$ will fly...
    markets down 1000 today and this is up.... yea,,,
  • C
    Charles
    When will this company start making money?
  • b
    boris
    crickets, no, cicadas...
  • D
    Dreezy
    Did anyone get the email to vote on these two things

    1. The approval of the increase in the number of authorized capital shares from 400,000,000 to 600,000,000.

    2. The ratification of the appointment of Soles, Heyn & Company LLP as the Corporation's independent accountants to audit the Corporation's financial statements for the fiscal year ending March 31, 2020.
  • B
    Big Panda
    First time GB buyer today 25k shares, good luck all!
  • D
    Dan
    the sale of GW pharmaceuticals for $200+ per share for their cannabis compound medical patents lays the groundwork for companies like GB getting scooped up by big pharma. hey one can hope...
  • J
    Jonathan
    Long time holder. I was down 99%, bought some more at about .045, so now only down about 6%. It appears that after three most recent announcement we have formed a floor in the .05 to .055 range. Hopefully this floor holds and we can end up trading up to the .08-.10 range. Thoughts are welcome.
  • U
    US~MSO~LONG
    $CVSI conversation
    UPDATE: The House Financial Services Committee recessed on Tuesday evening and plans to take up the cannabis banking bill and other scheduled legislation on Wednesday morning.

    $CVSI $TCNNF $CWBHF $ACRGF $GTBIF $GBLX $HRVSF $LHSIF
  • J
    James
    Gblx sells their LSU holdings for 8 million cash and has a chance to make an additional 8 million later under other provision in the 8k report filed on 9-06-19.
  • M
    Margarita Diver
    this company is about to open a 36000 sqft facility down the street from my house in baton rouge Louisiana. they are working with Louisiana state University with 5 year project. look it up
  • T
    Toby
    Sorry guys but I’m holding strong with my shares. I said it before I am not in the business to sale for a lost. It is either all or none for me. If my gamble does not pay out well all I can say is I never gamble away money that I can not afford to loose. That is why I diversify my portfolio. Holding 100 thousand plus on a hope and a dream.
  • D
    Dan
    big volume last few days. someone obviously knew about today's pr
    . this is great stuff I just hope there is still a company left before we see revenue. I'm a 6yr long and hope for the best.
  • D
    DEEZ NUTZ
    GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

    (PRNewsfoto/GB Sciences, Inc.)

    News provided by
    GB Sciences, Inc.

    Mar 19, 2019, 05:32 ET

    Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy

    LAS VEGAS, March 19, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today launched a global expansion strategy with the formation of GBS Global Biopharma Inc. ("GBS Global"), a cannabinoid medicine company based in Canada. GBS Global will expedite the development of clinical programs and IP currently indicated for 60 disease and health conditions.

    GBS Global is dedicated to developing cannabinoid medicines for medical cannabis, nutraceutical, and prescription drug markets. The Canadian entity will operate in a fully legal, open business environment allowing for greater international collaboration, cross border expansion, access to capital, and cost-effective R&D supported by the country's legal market, tax credits and favorable exchange rates.

    GBS Global proprietary discovery platform generates "complex mixture" cannabinoid/terpenoid active ingredients (APIs) for specific disease and health conditions. GBS Global researchers are working with scientists in the United States, Spain, and Greece on nutraceuticals, delivery technology, and prescription drug programs.

    "Canada's policies will allow GBS Global to bring our next-generation cannabinoid medications to market quickly, safely and legally. Canada's regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.," said GBS Global Board Chair and CEO of GB Sciences, Inc. John Poss. "This creates vital new opportunities for GBS Global, benefitting both our patients and investors."

    GBS Global intellectual property portfolio of natural and synthetic cannabinoid-based complex mixtures are indicated for Parkinson's (PD), neuropathic pain, and cardiac hypertrophy Rx programs in late pre-clinical stage of development. OTC programs for irritable bowel syndrome, sleep disorders, and psoriasis are at formulation stage in step with ongoing discussions with strategic partners in the field.

    "Developing our life sciences assets in Canada will expedite work to validate the safety and effectiveness of our proprietary therapeutics through expanded access to research partners and capital," said Dr. Andrea Small-Howard, Chief Science Officer and Board Member of GBS Global. "In addition, Canada's medical cannabis legislation provides an alternative channel for supporting health claims on some of our OTC patent-pending formulas. Plus, these products can be exported to Europe, the world's fastest growing market."
  • m
    melvin
    BREAKING NEWS: Just posted! We are open for business! Read and weeeeep! GLAD I DIDN't sell!! I told ya!!! We will have medical cannbis on the shelves BEFORE May 15th....watch and see..................https://finance.yahoo.com/news/gb-sciences-louisiana-receives-approvals-100200372.html
    Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation oper
    Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation oper
    finance.yahoo.com
  • B
    Bova
    I visited the Las Vegas Facility on Monday and I toured the grow rooms and the new Cannacure processing facility. The new build-out that is in process will increase production by 300 percent.

    This company is legit, once they are fully operational we should see the stock closer to $ 4.00.
  • D
    DEEZ NUTZ
    It is ALMOST HERE!!
    Tensions appear to have eased between state Commissioner of Agriculture Mike Strain and the LSU AgCenter over its growing partner in the state’s upstart medical marijuana program, GB Sciences of Louisiana. Though Strain publicly accused LSU and GBSL
    Tensions appear to have eased between state Commissioner of Agriculture Mike Strain and the LSU AgCenter over its growing partner in the state’s upstart medical marijuana program, GB Sciences of Louisiana. Though Strain publicly accused LSU and GBSL
    www.businessreport.com
  • B
    Big Panda
    Prior to buying I liked the testing potential GB could provide to every MJ producer who wants to differentiate their individual products to the market. License the testing and then show a road map to each states health organizations. Nice to see the news today. Not cheerleading just happy to watch this come together.
  • R
    RmR
    I think this could be a good move for the company. With the company only owning 50% and having to pay LSU yearly to use the license LSU is holding NOT GBs. It would take GBs a couple of years to see a profit at the LSU site. With LSU only being a 5 year contract and SLU coming on line soon. The state opening up the CBD sales market and hemp production. All kinds of companies are going to start selling health products. The money will be able to get the LV telco site up to the 600 lights from the 160 lights operating now . That will almost triple the income. In a state that allows GBs to sell medical and rec.
    The patients have been saying the price is to high at 200$ a month.
    200$ - 50% = 100$ - the price to operate the site and tax’s. Even At 100$ it would take GBs 80,000 bottles to get to 8mil$ 1500 patient x 100$ = 150,000 per month. 8mil @ 150,000 = 53 months or 4.4 years and that’s with out the cost of making it or tax’s.

    Davis estimates roughly 5,000 Louisianians consulted with physicians about the program, with some 1,500 patients receiving the tinctures. 
    https://www.businessreport.com/newsletters/gb-sciences-louisiana-sale-not-expected-to-disrupt-medical-marijuana-production
    Louisiana CBD permitted
    https://www.wdsu.com/article/hundreds-of-louisiana-businesses-permitted-to-sell-products-containing-cbd/28964291

    https://www.wwltv.com/article/news/health/houma-cbd-retailer-encouraged-by-new-louisiana-regulations/289-4191ce77-d7a7-4df6-b4de-dbddb6dea31e
    As GB Sciences Louisiana sheds its corporate parent to be fully owned by Lafayette-based Wellcana Group, GB Sciences Louisiana President John Davis says patients shouldn’t notice a change as that the transaction isn’t expected to disrupt medical mari
    As GB Sciences Louisiana sheds its corporate parent to be fully owned by Lafayette-based Wellcana Group, GB Sciences Louisiana President John Davis says patients shouldn’t notice a change as that the transaction isn’t expected to disrupt medical mari
    www.businessreport.com